AbbVie Inc Canadian Depository Receipt ABBV
Trading Information
- Previous Close Price
- CAD 27.73
- Day Range
- CAD 27.56–27.99
- 52-Week Range
- CAD 19.83–29.02
- Bid/Ask
- CAD 27.50 / CAD 28.00
- Market Cap
- CAD 32.07 Mil
- Volume/Avg
- 7,321 / 10,561
Key Statistics
- Price/Earnings (Normalized)
- 18.17
- Price/Sales
- 6.27
- Dividend Yield (Trailing)
- 3.21%
- Dividend Yield (Forward)
- 3.21%
- Total Yield
- 3.61%
Company Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 50,000
- Website
- http://www.abbvieinvestor.com
Competitors
Valuation
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 18.17 | 17.37 | 81.48 |
Price/Book Value | 50.13 | 6.58 | 60.37 |
Price/Sales | 6.27 | 4.61 | 21.11 |
Price/Cash Flow | 18.45 | 15.37 | 81.86 |
Price/Earnings
ABBV
MRK
LLY
Financial Strength
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.59 | 0.88 | 0.61 |
Current Ratio | 0.81 | 1.47 | 1.11 |
Interest Coverage | 3.51 | 13.07 | 15.08 |
Quick Ratio
ABBV
MRK
LLY
Profitability
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 13.66% | 15.46% | 13.15% |
Return on Equity (Normalized) | 189.99% | 41.15% | 69.16% |
Return on Invested Capital (Normalized) | 27.06% | 22.92% | 23.97% |
Return on Assets
ABBV
MRK
LLY
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Vcgwdhphm | Jqryq | $818.8 Bil | |||
| Johnson & Johnson
JNJ
| Klnwkwmk | Bwgcg | $388.5 Bil | |||
| AbbVie Inc
ABBV
| Snjcdmgnt | Jfds | $339.0 Bil | |||
| Merck & Co Inc
MRK
| Cfpqssv | Kfb | $286.7 Bil | |||
| Roche Holding AG ADR
RHHBY
| Shtvfrgn | Jpn | $255.9 Bil | |||
| AstraZeneca PLC ADR
AZN
| Wxsbclffw | Pfc | $241.9 Bil | |||
| Novartis AG ADR
NVS
| Tjqzfxd | Jlwl | $233.0 Bil | |||
| Amgen Inc
AMGN
| Xfyqgkjvc | Jxy | $171.5 Bil | |||
| Pfizer Inc
PFE
| Zvqnzsmby | Xhst | $164.2 Bil | |||
| Sanofi SA ADR
SNY
| Gxnqztbkn | Gplg | $142.8 Bil |
United States